Class III Device Recalls An Afterthought? Not So Fast . . .
This article was originally published in The Gray Sheet
Executive Summary
Low-risk class III medical device recalls sometimes fade into the background because they comprise only a sliver of the overall corrections and removals in a given year. Nevertheless, manufacturers should be aware that any decisions they make regarding class III actions are still going to receive FDA attention.
You may also be interested in...
Want To Make Faster Class I Recall Decisions? Then Put Women In The Boardroom, Study Says
Medical products companies that increase the number of women on their board of directors by 10% can see high-risk class I recalls initiated 16 days faster, a new study finds. “The Influence of Female Directors on Product Recall Decisions” also says that “changing from no female directors to one or more speeds up the time-to-recall for class I recalls by 35%, or a 28-day acceleration.” The study further claims manufacturers conduct more class III recalls when women are represented in the boardroom.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.